Meeting
2018 ASCO Annual Meeting
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.
Authors
Erlinda Maria Gordon
Sarcoma Oncology Center, Santa Monica, CA
Erlinda Maria Gordon , Victoria S. Chua-Alcala , Katherine Kim , Shiva Sreenath Andrali , Marie Del Rosario , William W. Tseng , Seth Pollack , Sant P. Chawla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT 03138161
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS11591)
DOI
10.1200/JCO.2018.36.15_suppl.TPS11591
Abstract #
TPS11591
Poster Bd #
333b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS).
First Author: Erlinda Maria Gordon
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Sant P. Chawla
Poster
2019 ASCO Annual Meeting
SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara